Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-26 @ 12:16 PM
Ignite Modification Date:
2025-12-26 @ 12:16 PM
NCT ID:
NCT02498600
Group ID:
EG001
Title:
Treatment II
Description:
Nivolumab/Ipilimumab: Nivolumab 3mg/kg IV and Ipilimumab 1mg/kg IV once every 3 weeks x 4 doses (induction phase)\*, followed by Nivolumab 3 mg/kg IV every 2 weeks (maintenance phase), for a maximum of 42 doses of maintenance therapy, until disease progression or until development of unacceptable toxicity, whichever comes first.
1 Cycle = 3 weeks for induction phase
1 Cycle = 4 weeks for maintenance phase
Deaths Number Affected:
21
Deaths Number At Risk:
None
Serious Number Affected:
27
Serious Number At Risk:
51
Other Number Affected:
51
Other Number At Risk:
51
Study:
NCT02498600
Results Section:
NCT02498600
Adverse Events Module:
NCT02498600